Halozyme Therapeutics, Inc. (0J2O.L)
USD 56.78
(-5.49%)
USD 56.78
(-5.49%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 127.6 Million USD | 27.44% |
| 2022 | 100.12 Million USD | 85.73% |
| 2021 | 53.9 Million USD | -11.26% |
| 2020 | 60.74 Million USD | 106.91% |
| 2019 | 29.35 Million USD | 29.76% |
| 2018 | 22.62 Million USD | 339.66% |
| 2017 | 5.14 Million USD | -64.81% |
| 2016 | 14.62 Million USD | 54.1% |
| 2015 | 9.48 Million USD | 48.13% |
| 2014 | 6.4 Million USD | 3.83% |
| 2013 | 6.16 Million USD | 131.03% |
| 2012 | 2.67 Million USD | 370.8% |
| 2011 | 567.26 Thousand USD | 193.28% |
| 2010 | 193.42 Thousand USD | -83.32% |
| 2009 | 1.15 Million USD | 162.74% |
| 2008 | 441.32 Thousand USD | -37.26% |
| 2007 | 703.46 Thousand USD | 58.98% |
| 2006 | 442.49 Thousand USD | 58.62% |
| 2005 | 278.95 Thousand USD | 438.31% |
| 2004 | 51.82 Thousand USD | 0.0% |
| 2003 | - USD | 0.0% |
| 2002 | - USD | 0.0% |
| 2001 | - USD | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 168.54 Million USD | 32.08% |
| 2024 Q2 | 159.31 Million USD | -5.48% |
| 2024 Q3 | 131.41 Million USD | -17.51% |
| 2023 Q4 | 127.6 Million USD | -1.02% |
| 2023 Q2 | 132.4 Million USD | 23.14% |
| 2023 Q1 | 107.52 Million USD | 7.39% |
| 2023 Q3 | 128.92 Million USD | -2.63% |
| 2023 FY | 127.6 Million USD | 27.44% |
| 2022 FY | 100.12 Million USD | 85.73% |
| 2022 Q4 | 100.12 Million USD | -3.05% |
| 2022 Q1 | 47.76 Million USD | -11.4% |
| 2022 Q2 | 97.61 Million USD | 104.38% |
| 2022 Q3 | 103.27 Million USD | 5.8% |
| 2021 Q2 | 58.55 Million USD | 0.36% |
| 2021 Q1 | 58.34 Million USD | -3.96% |
| 2021 Q4 | 53.9 Million USD | -3.7% |
| 2021 Q3 | 55.97 Million USD | -4.4% |
| 2021 FY | 53.9 Million USD | -11.26% |
| 2020 Q1 | 41.45 Million USD | 41.19% |
| 2020 Q3 | 57.69 Million USD | 19.53% |
| 2020 Q4 | 60.74 Million USD | 5.29% |
| 2020 FY | 60.74 Million USD | 106.91% |
| 2020 Q2 | 48.27 Million USD | 16.45% |
| 2019 Q4 | 29.35 Million USD | -18.56% |
| 2019 FY | 29.35 Million USD | 29.76% |
| 2019 Q3 | 36.05 Million USD | -17.88% |
| 2019 Q2 | 43.9 Million USD | 40.52% |
| 2019 Q1 | 31.24 Million USD | 38.08% |
| 2018 FY | 22.62 Million USD | 339.66% |
| 2018 Q4 | 22.62 Million USD | 23.74% |
| 2018 Q3 | 18.28 Million USD | 117.57% |
| 2018 Q2 | 8.4 Million USD | 91.3% |
| 2018 Q1 | 4.39 Million USD | -14.63% |
| 2017 Q2 | 15.17 Million USD | 6.17% |
| 2017 FY | 5.14 Million USD | -64.81% |
| 2017 Q1 | 14.29 Million USD | -2.28% |
| 2017 Q4 | 5.14 Million USD | -44.85% |
| 2017 Q3 | 9.33 Million USD | -38.5% |
| 2016 Q4 | 14.62 Million USD | 13.78% |
| 2016 FY | 14.62 Million USD | 54.1% |
| 2016 Q2 | 10.75 Million USD | 3.96% |
| 2016 Q1 | 10.34 Million USD | 9.02% |
| 2016 Q3 | 12.85 Million USD | 19.5% |
| 2015 FY | 9.48 Million USD | 48.13% |
| 2015 Q3 | 11.1 Million USD | 43.74% |
| 2015 Q1 | 7.48 Million USD | 16.8% |
| 2015 Q2 | 7.72 Million USD | 3.22% |
| 2015 Q4 | 9.48 Million USD | -14.52% |
| 2014 FY | 6.4 Million USD | 3.83% |
| 2014 Q2 | 7.11 Million USD | 5.16% |
| 2014 Q3 | 6.91 Million USD | -2.78% |
| 2014 Q1 | 6.76 Million USD | 9.64% |
| 2014 Q4 | 6.4 Million USD | -7.37% |
| 2013 Q4 | 6.16 Million USD | 60.41% |
| 2013 Q2 | 2.46 Million USD | -9.88% |
| 2013 Q1 | 2.73 Million USD | 2.5% |
| 2013 FY | 6.16 Million USD | 131.03% |
| 2013 Q3 | 3.84 Million USD | 55.91% |
| 2012 FY | 2.67 Million USD | 370.8% |
| 2012 Q4 | 2.67 Million USD | 22.17% |
| 2012 Q3 | 2.18 Million USD | 22.54% |
| 2012 Q2 | 1.78 Million USD | 19.18% |
| 2012 Q1 | 1.49 Million USD | 163.86% |
| 2011 Q4 | 567.26 Thousand USD | 448.38% |
| 2011 FY | 567.26 Thousand USD | 193.28% |
| 2011 Q2 | 83.84 Thousand USD | -66.25% |
| 2011 Q1 | 248.47 Thousand USD | 28.46% |
| 2011 Q3 | 103.44 Thousand USD | 23.37% |
| 2010 Q1 | 1.15 Million USD | 0.0% |
| 2010 Q2 | 1.08 Million USD | -6.7% |
| 2010 Q3 | 1.07 Million USD | -0.49% |
| 2010 FY | 193.42 Thousand USD | -83.32% |
| 2010 Q4 | 193.42 Thousand USD | -82.03% |
| 2009 Q2 | 803.53 Thousand USD | 41.78% |
| 2009 Q3 | 1.23 Million USD | 54.1% |
| 2009 Q4 | 1.15 Million USD | -6.36% |
| 2009 FY | 1.15 Million USD | 162.74% |
| 2009 Q1 | 566.76 Thousand USD | 28.42% |
| 2008 Q3 | 525.42 Thousand USD | -19.07% |
| 2008 Q2 | 649.25 Thousand USD | -4.39% |
| 2008 Q1 | 679.08 Thousand USD | -3.47% |
| 2008 Q4 | 441.32 Thousand USD | -16.01% |
| 2008 FY | 441.32 Thousand USD | -37.26% |
| 2007 Q3 | 713.3 Thousand USD | 15.0% |
| 2007 Q2 | 620.26 Thousand USD | 30.53% |
| 2007 Q1 | 475.18 Thousand USD | 7.39% |
| 2007 FY | 703.46 Thousand USD | 58.98% |
| 2007 Q4 | 703.46 Thousand USD | -1.38% |
| 2006 Q4 | 442.49 Thousand USD | 89.29% |
| 2006 Q2 | 414.05 Thousand USD | 44.68% |
| 2006 Q3 | 233.76 Thousand USD | -43.54% |
| 2006 FY | 442.49 Thousand USD | 58.62% |
| 2006 Q1 | 286.18 Thousand USD | 2.59% |
| 2005 Q3 | 45.35 Thousand USD | 45.88% |
| 2005 Q1 | 47.14 Thousand USD | -9.02% |
| 2005 Q2 | 31.09 Thousand USD | -34.05% |
| 2005 Q4 | 278.95 Thousand USD | 515.07% |
| 2005 FY | 278.95 Thousand USD | 438.31% |
| 2004 Q2 | - USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2004 FY | 51.82 Thousand USD | 0.0% |
| 2004 Q4 | 51.82 Thousand USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2003 Q4 | - USD | 0.0% |
| 2003 Q3 | - USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| 2003 Q1 | - USD | 0.0% |
| 2003 Q2 | - USD | 0.0% |
| 2002 Q3 | - USD | 0.0% |
| 2002 Q1 | - USD | 0.0% |
| 2002 Q2 | - USD | 0.0% |
| 2002 Q4 | - USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| uniQure N.V. | 12.02 Million USD | -961.219% |
| Agios Pharmaceuticals, Inc. | 19.07 Million USD | -568.909% |
| Amicus Therapeutics, Inc. | 59.69 Million USD | -113.751% |
| Atara Biotherapeutics, Inc. | 9.7 Million USD | -1214.661% |
| bluebird bio, Inc. | 22.91 Million USD | -456.748% |
| Cara Therapeutics, Inc. | 2.82 Million USD | -4423.254% |
| Imunon, Inc. | - USD | -Infinity% |
| Editas Medicine, Inc. | - USD | -Infinity% |
| IQVIA Holdings Inc. | - USD | -Infinity% |
| Mettler-Toledo International Inc. | 385.86 Million USD | 66.931% |
| Myriad Genetics, Inc. | 20.1 Million USD | -534.831% |
| Neurocrine Biosciences, Inc. | 38.3 Million USD | -233.162% |
| Supernus Pharmaceuticals, Inc. | 77.4 Million USD | -64.842% |
| Verastem, Inc. | - USD | -Infinity% |
| Walgreens Boots Alliance, Inc. | 8.32 Billion USD | 98.466% |
| Waters Corporation | 516.23 Million USD | 75.282% |
| Thermo Fisher Scientific Inc. | 5.08 Billion USD | 97.492% |
| Biogen Inc. | 2.52 Billion USD | 94.951% |
| Nektar Therapeutics | 16.1 Million USD | -692.504% |
| Perrigo Company plc | 1.14 Billion USD | 88.816% |
| Dynavax Technologies Corporation | 53.29 Million USD | -139.446% |
| Illumina, Inc. | 587 Million USD | 78.262% |
| Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Iovance Biotherapeutics, Inc. | 10.37 Million USD | -1130.245% |
| Heron Therapeutics, Inc. | 42.11 Million USD | -203.018% |
| Unity Biotechnology, Inc. | - USD | -Infinity% |
| BioMarin Pharmaceutical Inc. | 1.1 Billion USD | 88.475% |
| Sangamo Therapeutics, Inc. | - USD | -Infinity% |
| Evolus, Inc. | 10.99 Million USD | -1060.22% |
| Adicet Bio, Inc. | - USD | -Infinity% |
| Aclaris Therapeutics, Inc. | - USD | -Infinity% |
| Regeneron Pharmaceuticals, Inc. | 2.58 Billion USD | 95.055% |
| Esperion Therapeutics, Inc. | 65.62 Million USD | -94.446% |
| FibroGen, Inc. | 41.56 Million USD | -206.991% |
| Agilent Technologies, Inc. | 1.03 Billion USD | 87.624% |
| OPKO Health, Inc. | 65.69 Million USD | -94.227% |
| Homology Medicines, Inc. | - USD | -Infinity% |
| Geron Corporation | - USD | -Infinity% |
| Alnylam Pharmaceuticals, Inc. | 89.14 Million USD | -43.137% |
| Exelixis, Inc. | 17.32 Million USD | -636.599% |
| Viking Therapeutics, Inc. | - USD | -Infinity% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | - USD | -Infinity% |
| Zoetis Inc. | 2.56 Billion USD | 95.023% |
| Axsome Therapeutics, Inc. | 15.13 Million USD | -743.086% |
| Abeona Therapeutics Inc. | -2.44 Million USD | 5320.99% |
| Vertex Pharmaceuticals Incorporated | 738.8 Million USD | 82.729% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Ionis Pharmaceuticals, Inc. | 28.42 Million USD | -348.904% |
| Sarepta Therapeutics, Inc. | 322.85 Million USD | 60.478% |
| Corcept Therapeutics Incorporated | 7.73 Million USD | -1550.724% |
| Blueprint Medicines Corporation | 21.22 Million USD | -501.239% |
| Insmed Incorporated | 83.24 Million USD | -53.278% |
| TG Therapeutics, Inc. | 39.82 Million USD | -220.42% |
| Incyte Corporation | 62.97 Million USD | -102.631% |
| Emergent BioSolutions Inc. | 328.9 Million USD | 61.204% |